The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Lyell Immunopharma Inc. (LYEL) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $2.39. The Lyell Immunopharma Inc. has recorded 61,941 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Lyell Immunopharma to Participate in Upcoming Investor Conferences.
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $2.39 and fluctuated between $2.4650 as its day high and $2.3100 as its day low. The current market capitalization of Lyell Immunopharma Inc. is $584.24M. A total of 1.46 million shares were traded on the day, compared to an average of 971.53K shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, LYEL has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 1 BUYs and 1 SELLs from insiders. Insiders purchased 145,380 shares during that period but sold 11,100.
In the most recent transaction, Klausner Richard sold 58,020 shares of LYEL for 2.28 per share on Aug 15. After the transaction, the Director now owns 930,880 company shares. In a previous transaction on Sep 23, Klausner Richard sold 11,100 shares at 6.40 per share. LYEL shares that Director owns now total 988,900.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for LYEL in the last 3 months, the mean price target is $6.80 with high estimates of $10.00 and low estimates of $4.00. In terms of 52-week highs and lows, LYEL has a high of $8.74 and a low of $1.77.
As of this writing, LYEL has an earnings estimate of -$0.25 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of -$0.22 per share and a lower estimate of -$0.29. The company reported an EPS of -$0.23 in the last quarter, which was 17.90% higher than expectations of -$0.28.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. LYEL’s latest balance sheet shows that the firm has $614.79M in Cash & Short Term Investments as of fiscal 2021. There were $67.82M in debt and $46.74M in liabilities at the time. Its Book Value Per Share was $2.95, while its Total Shareholder’s Equity was $929.79M.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for LYEL is Buy with a score of 3.80.